Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4.13B 620M 556M 514M 465M 870M 59.01B 880M 6.14B 2.45B 30.88B 2.33B 2.28B 98.03B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.99B 749M 672M 621M 562M 1.05B 71.3B 1.06B 7.42B 2.96B 37.31B 2.81B 2.75B 118B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.3%
Yield 2024
0.37%
Yield 2025 0.06%
10-27 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
09-21 Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) added to S&P Global BMI Index CI
08-21 Realcan Pharmaceutical Group Co., Ltd. Approves the Election of Lv Kaiqiang and Wu Bin as Independent Director CI
08-21 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-20 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-07 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
30/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
26/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day+0.72%
1 week-5.70%
Current month-14.07%
1 month-13.54%
3 months+3.31%
6 months-12.73%
Current year-12.73%
1 week 2.72
Extreme 2.72
2.93
1 month 2.72
Extreme 2.72
3.38
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 26/04/2021
President 61 26/05/2023
Corporate Officer/Principal 40 30/10/2019
Director TitleAgeSince
Chairman 61 21/11/2009
Director/Board Member 43 21/11/2009
Chairman 48 08/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
12/5/23 Sell

Founder

15,000,000 1.2902%
30/3/23 Sell

Founder

13,040,000 1.1260%
30/3/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%-5.70%-2.77%-19.25% 615M
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.21%+1.16%+36.30%+66.84% 402.81B
Weighted average by Cap. +0.25%+1.55%+44.49%+89.00%

Financials

2024 2025
Net sales 7.97B 1.19B 1.07B 991M 898M 1.68B 114B 1.7B 11.85B 4.72B 59.55B 4.48B 4.39B 189B 7.3B 1.09B 982M 908M 822M 1.54B 104B 1.55B 10.85B 4.32B 54.54B 4.11B 4.02B 173B
Net income 20.62M 3.09M 2.78M 2.57M 2.32M 4.34M 295M 4.39M 30.68M 12.22M 154M 11.61M 11.36M 489M 16.07M 2.41M 2.16M 2M 1.81M 3.38M 230M 3.42M 23.91M 9.52M 120M 9.05M 8.85M 381M
Net Debt 1.6B 239M 215M 198M 180M 336M 22.79B 340M 2.37B 945M 11.93B 898M 879M 37.86B 860M 129M 116M 107M 96.94M 181M 12.29B 183M 1.28B 510M 6.43B 484M 474M 20.42B
Projected Income Statement - Annual - Realcan Pharmaceutical Group Co., Ltd.
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
28/10/26 CN¥2.810 +0.72% 36,907,252
27/10/26 CN¥2.790 -4.12% 50,043,591
26/10/26 CN¥2.910 +0.34% 44,423,600
23/10/26 CN¥2.900 +1.75% 61,091,800
22/10/26 CN¥2.850 -4.36% 64,525,600
  1. Stock Market
  2. Stocks
  3. 002589 Stock